News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
826,471 Results
Type
Article (85354)
Company Profile (695)
Press Release (740422)
Section
Business (231839)
Career Advice (4100)
Deals (39635)
Drug Delivery (112)
Drug Development (90513)
Employer Resources (194)
FDA (17902)
Job Trends (17261)
News (394824)
Policy (39576)
Tag
Academia (2972)
Alliances (56335)
Alzheimer's disease (1303)
Approvals (17832)
Artificial intelligence (117)
Bankruptcy (394)
Best Places to Work (12363)
Biosimilars (83)
Biotechnology (478)
Breast cancer (95)
Cancer (843)
Career advice (3508)
Cell therapy (217)
Clinical research (70958)
Collaboration (307)
Compensation (142)
COVID-19 (2776)
Cystic fibrosis (79)
Data (750)
Diabetes (98)
Diagnostics (6565)
Earnings (93550)
Employer resources (166)
Events (125604)
Executive appointments (214)
FDA (18241)
Featured Employer (79)
Funding (252)
Gene therapy (162)
GLP-1 (619)
Government (5014)
Healthcare (20615)
Infectious disease (2836)
Inflammatory bowel disease (114)
Interviews (807)
IPO (17515)
Job creations (5176)
Job search strategy (2853)
Layoffs (479)
Legal (10010)
Lung cancer (142)
Manufacturing (153)
Medical device (14233)
Medtech (14238)
Mergers & acquisitions (22006)
Metabolic disorders (337)
Neuroscience (1534)
NextGen Class of 2024 (7642)
Non-profit (5046)
Northern California (1081)
Obesity (193)
Opinion (241)
Patents (88)
People (63882)
Pharmaceutical (136)
Phase I (21830)
Phase II (30821)
Phase III (23253)
Pipeline (191)
Podcasts (85)
Postmarket research (3533)
Preclinical (9869)
Radiopharmaceuticals (241)
Rare diseases (175)
Real estate (7366)
Regulatory (25733)
Research institute (2637)
Resumes & cover letters (648)
Southern California (974)
Startups (4272)
United States (10830)
Vaccines (604)
Weight loss (169)
Date
Today (189)
Last 7 days (699)
Last 30 days (2413)
Last 365 days (35754)
2024 (30139)
2023 (42566)
2022 (53928)
2021 (58726)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1261)
Arizona (210)
Asia (49107)
Australia (8659)
California (2505)
Canada (989)
China (192)
Connecticut (100)
Europe (112387)
Florida (301)
Illinois (311)
Indiana (168)
Kansas (102)
Maryland (518)
Massachusetts (2174)
Michigan (135)
Minnesota (229)
New Jersey (761)
New York (754)
North Carolina (752)
Northern California (1081)
Ohio (111)
Pennsylvania (637)
South America (1646)
Southern California (974)
Texas (322)
Washington State (319)
826,471 Results for "peak bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Akari Therapeutics, Plc and Peak Bio Inc. announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC platform technology and Akari’s PAS-nomacopan Geographic Atrophy program.
May 1, 2024
·
16 min read
Press Releases
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
October 15, 2024
·
13 min read
Deals
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics, Plc and Peak Bio Inc. announce a definitive agreement to merge as equals in an all-stock transaction.
March 5, 2024
·
17 min read
Immuron CEO Steven Lydeamore to present at Peak Sky High
Immuron Limited, an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1, 2024.
May 31, 2024
·
6 min read
Biotech Bay
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics, Plc and Peak Bio Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction.
March 5, 2024
·
17 min read
Biotech Bay
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Peak Bio, Inc. (“Peak Bio” or the “Company”) (OTCQB) PK: PKBO), announced that it was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office (USPTO).
January 4, 2024
·
7 min read
Business
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.
August 31, 2023
·
6 min read
Biotech Beach
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials
Bright Peak Therapeutics, a biotechnology company developing next-generation, multifunctional immunotherapies, announced that it raised $90 million in a Series C financing.
June 11, 2024
·
2 min read
Biotech Bay
Peak Bio, Inc. Announces Up-listing to OTCQB Market
Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer.
August 31, 2023
·
7 min read
Drug Development
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
Cogent Biosciences, Inc. announced positive updated lead-in data from the company’s ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors.
May 23, 2024
·
8 min read
1 of 82,648
Next
